Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07314320 · ClinicalTrials.gov registry record · Phase 1
A Study to Detect Radioactivity of [14C]-OPC-167832 in Urine and Feces in Healthy Men
A Phase 1 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT07314320: Completed Phase 1 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.
NCT07314320 is a Phase 1 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07314320, a Phase 1 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the relative amounts of radioactivity excreted in urine and feces following a single oral dose of \[14C\]-OPC-167832 in healthy male participants.
Interventions
- DRUG [14C]-OPC-167832
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2023-11-20 |
| Est. Completion | 2023-12-27 |
| Phase | Phase 1 |
What the finished NCT07314320 record still lists
NCT07314320 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which [14C]-OPC-167832 is the first listed.
NCT07314320 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07314320 about?
NCT07314320 is a clinical study titled "A Study to Detect Radioactivity of [14C]-OPC-167832 in Urine and Feces in Healthy Men". The purpose of this study is to determine the relative amounts of radioactivity excreted in urine and feces following a single oral dose of \[14C\]-OPC-167832 in healthy male participants.
What is the current status of trial NCT07314320?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2023-11-20. Estimated completion is 2023-12-27.
What interventions are being tested in trial NCT07314320?
The interventions under investigation include: [14C]-OPC-167832 (DRUG).
Who is sponsoring clinical trial NCT07314320?
This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07314320's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI